1. Qhov tshwm sim ntawm pulmonary hypertension yog tsawg, tab sis qhov kev pheej hmoo siab heev. 75 feem pua ntawm cov neeg mob tau mob siab rau lub hnub nyoog ntawm 20-40 xyoo, thiab qhov nruab nrab hnub nyoog pib tsuas yog 36 xyoo. Yog tias tsis kho raws sijhawm, lub sijhawm muaj sia nyob tsuas yog ob mus rau peb xyoos, thiab tus nqi ntawm 5-xyoo ciaj sia tsuas yog 21 feem pua; CTEPH feem ntau yog tus cwj pwm los ntawm qhov tsis tuaj yeem thim rov qab thromboembolism nyob rau hauv qhov ze lossis qhov kawg ntawm cov hlab ntsha pulmonary, feem ntau yog theem nrab rau kev sib cais lossis rov ua dua pulmonary embolism. Hauv kev xyaum kho mob, nws tuaj yeem ua rau mob hnyav thiab mob plawv tsis ua haujlwm, thaum kawg ua rau tuag; Txoj kev tshawb fawb ntawm PAH rau npe hauv Suav teb qhia tau hais tias qhov muaj sia nyob ib xyoos ntawm IPAH thiab cov neeg mob caj ces PAH uas tsis tau txais kev kho mob hauv Suav teb tsuas yog 68.0 feem pua. Txawm li cas los xij, tom qab tau txais kev kho tshuaj txaus, qhov kev muaj sia nyob ib xyoos tuaj yeem nce mus rau 85.4 feem pua.
2. Lioxiguate yog ib tug soluble guanylate cyclase activator thiab ib qho tseem ceeb teeb liab transduction enzyme, uas yuav tsum tau activated los ntawm nitric oxide (NO) catalyze hloov dua siab tshiab ntawm guanosine triphosphate (GTP) mus rau lub thib ob messenger cyclic guanosine phosphate (cGMP). Thawj txoj kev tshawb fawb yog tsim los ntawm lub teb chaws Yelemees thiab tau pom zoo los ntawm FDA rau kev kho mob pulmonary hypertension hauv 2013. Nws tau pom zoo muag hauv Suav teb xyoo 2018 ua thawj sGC agonist nkag mus rau Tuam Tshoj. Nws yog tib lub hom phiaj tshuaj rau kev kho mob pulmonary hypertension nrog dual indications rau PAH thiab CTEPH nyob rau hauv Tuam Tshoj, thiab kuj yog thawj thiab tsuas pom zoo tshuaj kho mob rau CTEPH nyob rau hauv European Union.
3. Cov kev tshawb fawb soj ntsuam tau pom tias kev kho mob pulmonary arterial hypertension nrog Lioxigua tsis yog tsuas yog siv tau zoo xwb, tab sis kuj tuaj yeem ua rau muaj kev cuam tshuam me me. Nws cov bioavailability kiag li yog hais txog 94 feem pua, thiab kev tswj qhov ncauj tsis cuam tshuam rau nws cov bioavailability vim muaj zaub mov.
4. Kev muag khoom thoob ntiaj teb ntawm Leosigua xyoo 2019 yog $ 456 lab, thiab Cortellis kwv yees tias nws qhov muag hauv 2022 yuav ncav cuag $ 1.3 nphom, ib lub teb chaws Class B cov khoom pov hwm kho mob. Hauv thawj peb lub hlis twg ntawm 2021, cov nyiaj tau los muag hauv tsev kho mob tau txog ze li 30 lab, nce 275 feem pua ntawm xyoo.
5. Tsuas yog tus thawj formulation muaj nyob rau hauv lub khw, thiab tsuas yog cov tshuaj uas muaj dual indications rau PAH thiab CTEPH. Peb lub tuam txhab tuaj yeem muab cov khoom zoo tuaj txawv teb chaws.
qhia:
Chronic thromboembolic pulmonary hypertension (CTEPH) yog siv los kho cov neeg laus cov neeg mob uas tsis tu ncua lossis rov tshwm sim CTEPH lossis tsis ua haujlwm CTEPH tom qab phais, thiab World Health Organization Heart Function Classification (WHO FC) yog II-III los txhim kho lawv lub cev muaj zog.
Arterial pulmonary hypertension (PAH) yog kho raws li ib yam tshuaj, los yog ua ke nrog endothelin receptor antagonists los yog prostacyclin, los txhim kho lub cev muaj zog rau cov neeg laus nrog arterial pulmonary hypertension (PAH) thiab WHO-FC qib II-III. Kev kuaj pom tseeb ntawm cov khoom no feem ntau suav nrog cov neeg mob uas muaj idiopathic lossis hereditary arterial pulmonary hypertension lossis connective cov ntaub so ntswg kab mob ntsig txog arterial pulmonary hypertension hauv WHO cardiac function grading II-III.